Grand Rapids, MINCT07263594Now EnrollingIRB Ready

Gastrointestinal Cancer Clinical Trial in Grand Rapids, MI

Access cutting-edge gastrointestinal cancer treatment through this phase 1/2 clinical trial at a research site in Grand Rapids. Study-provided care at no cost to qualified participants.

Sponsored by DualityBio Inc.

Quick Self-Assessment

See if you qualify for this Grand Rapids location

Preparing your pre-screening questions…

Expert Care in Grand Rapids

Access gastrointestinal cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related gastrointestinal cancer treatment provided free

Apply for This Grand Rapids Location

Check if you qualify for this gastrointestinal cancer clinical trial in Grand Rapids, MI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Grand Rapids

    Convenient for MI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Grand Rapids site if eligible
  4. 4Begin participation

About This Gastrointestinal Cancer Study in Grand Rapids

This study, the first clinical trial, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of DB-1324.

Sponsor: DualityBio Inc.

Who Can Participate

Inclusion Criteria

Pathologically documented advanced/unresectable, or metastatic GI tumor.
Have relapsed or progressed on or after standard systemic treatments, or are intolerant to standard treatment, or for which no standard treatment is available.
At least one measurable lesion as assessed by the investigator according to response evaluation criteria in RECIST v1.1.
Has a life expectancy of ≥ 3 months.
Has an ECOG PS of 0-1.
Has LVEF ≥ 50% by either ECHO or MUGA within 28 days before enrollment.
Has adequate organ functions within 7 days prior to Day 1 of Cycle 1.
Has an adequate treatment washout period before Day 1 of Cycle 1.
Participants are willing to provide archived tumor tissue or undergo a tumor biopsy for the measurement of CDH17 levels and other biomarkers.
Other protocol-defined Inclusion criteria apply.

Exclusion Criteria

Prior treatment with CDH17 targeted therapy.
Prior treatment with ADC with topoisomerase I inhibitor.
Has chronic enteritis or inflammatory bowel disease. Or has clinically significant bleeding of GI tract or adjacent organs within 1 month prior to the first dose of study treatment. Or has clinically significant obstruction and/or perforation and/or fistulae (including prior GI fistula operation) of GI tract or adjacent tissues within 6 months prior to the first dose of study treatment.
Uncontrolled or significant cardiovascular disease.
Has a medical history of cerebrovascular accident including transient ischemic attack within 6 months before enrollment.
Has a history of (non-infectious) ILD/pneumonitis that required steroids, or has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
Have a lung-specific intercurrent clinically significant illness.
Has an uncontrolled infection requiring intravenous injection of antibiotics, antivirals, or antifungals.
Has clinically active brain metastases.
Has unresolved toxicities from previous anticancer therapy.
Other protocol-defined Exclusion criteria apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Grand Rapids?

Yes, this clinical trial (NCT07263594) has an active research site in Grand Rapids, MI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Gastrointestinal Cancer Treatment Options in Grand Rapids, MI

If you're searching for gastrointestinal cancer treatment options in Grand Rapids, MI, this clinical trial (NCT07263594) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Grand Rapids research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced gastrointestinal cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all gastrointestinal cancer clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Grand Rapids, MI

See all ankylosing spondylitis clinical trials recruiting in Grand Rapids — not just this study.

Browse Ankylosing Spondylitis Trials in Grand Rapids →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsGeographic Atrophy TrialsOsteogenesis Imperfecta TrialsAll Conditions →

Ready to Join in Grand Rapids?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Grand Rapids, MI